Scientists test copycat drug in healthy volunteers

NCT ID NCT07246252

Summary

This study aimed to see if a new manufacturing version of the drug Omalizumab (called Process-Changed CMAB007) behaves similarly to the original drug (Xolair) in the body. It involved 114 healthy Chinese male volunteers who received a single injection. Researchers monitored the participants for over 3 months to compare how the drugs were processed, their safety, and whether they triggered an immune response.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Shanghai Xuhui Central Hospital, Shanghai

    Shanghai, China

Conditions

Explore the condition pages connected to this study.